Literature DB >> 15793862

Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis.

Hu Zhang1, Qin Ouyang, Zhong-Hui Wen, Claudio Fiocchi, Wei-Ping Liu, Dai-Yun Chen, Feng-Yuan Li.   

Abstract

AIM: Glucocorticoid (GC) resistant ulcerative colitis (UC) remains a serious disease and is difficult to manage. Although the molecular basis of GC insensitivity is still unknown, GC receptors (GRalpha and GRbeta) may play an important role in it. This study was aimed to investigate the relationship between the expression of GRalpha and GRbeta in colonic mucosal cells of patients with UC, the efficacy of GC therapy and the intensity of inflammation.
METHODS: Twenty-five cases of UC were classified into: GC sensitive (n = 16) and GC resistant (n = 9) cases. Patients consisted of mild (n = 6), moderate (n = 8) and severe (n = 11) cases. GRalpha and GRbeta expression in colonic mucosal specimens were investigated by immunohistochemistry, and compared between GC resistant and sensitive groups, and also among various degrees of inflammation.
RESULTS: All cases were positive for GRalpha and GRbeta expression. Both positive association between GRalpha expression and the response of UC to GC and strong negative association between GRbeta expression and the response of UC to GC were identified. There was no significant association between GRalpha/GRbeta expression and the degree of inflammation of UC.
CONCLUSION: These findings suggest that both GRalpha and GRbeta may play an important role in the action of GC, and that GRbeta functions as a dominant negative inhibitor of GRalpha. Expression of GRalpha and GRbeta in colonic mucosal cells of patients with UC may serve as predictors of glucocorticoid response, but can not function as markers of inflammatory intensity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793862      PMCID: PMC4305872          DOI: 10.3748/wjg.v11.i12.1775

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin.

Authors:  Hui-Fei Cui; Xue-Liang Jiang
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

2.  [The expression of glucocorticoid receptor beta messenger RNA in peripheral white blood cells of hormone-resistant nephrotic syndrome patients].

Authors:  Y Liu; L Song; B Li
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2001-11

Review 3.  Glucocorticoid-resistant asthma.

Authors:  Tuck-Kay Loke; Ana R Sousa; Christopher J Corrigan; Tak H Lee
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

4.  The phase-shift mutation in the glucocorticoid receptor gene: potential etiologic significance of neuroendocrine mechanisms in lupus nephritis.

Authors:  T Jiang; S Liu; M Tan; F Huang; Y Sun; X Dong; W Guan; L Huang; F Zhou
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

5.  Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma.

Authors:  Q A Hamid; S E Wenzel; P J Hauk; A Tsicopoulos; B Wallaert; J J Lafitte; G P Chrousos; S J Szefler; D Y Leung
Journal:  Am J Respir Crit Care Med       Date:  1999-05       Impact factor: 21.405

Review 6.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

7.  Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis.

Authors:  M Boirivant; R Pica; R DeMaria; R Testi; F Pallone; W Strober
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

8.  The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): tissue levels, mechanism of action, and potential physiologic role.

Authors:  M de Castro; S Elliot; T Kino; C Bamberger; M Karl; E Webster; G P Chrousos
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

9.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

Review 10.  Corticosteroids for the management of ulcerative colitis and Crohn's disease.

Authors:  D P Jewell
Journal:  Gastroenterol Clin North Am       Date:  1989-03       Impact factor: 3.806

View more
  7 in total

1.  Probing Dominant Negative Behavior of Glucocorticoid Receptor β through a Hybrid Structural and Biochemical Approach.

Authors:  Jungki Min; Lalith Perera; Juno M Krahn; Christine M Jewell; Andrea F Moon; John A Cidlowski; Lars C Pedersen
Journal:  Mol Cell Biol       Date:  2018-03-29       Impact factor: 4.272

Review 2.  Alpha and beta glucocorticoid receptors: relevance in airway diseases.

Authors:  Laura Pujols; Joaquim Mullol; César Picado
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

3.  Evidence for a glucocorticoid receptor beta splice variant in the rat and its physiological regulation in liver.

Authors:  Debra C DuBois; Siddharth Sukumaran; William J Jusko; Richard R Almon
Journal:  Steroids       Date:  2012-12-19       Impact factor: 2.668

Review 4.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 5.  Naturally occurring C-terminal splice variants of nuclear receptors.

Authors:  Michiel van der Vaart; Marcel J M Schaaf
Journal:  Nucl Recept Signal       Date:  2009-06-19

6.  Editorial: COVID-19 and the Digestive System.

Authors:  Chunxiang Ma; Weiguo Dong; Bo Shen; Hu Zhang
Journal:  Front Med (Lausanne)       Date:  2022-03-30

7.  Effects of different doses of methylprednisolone therapy on acute respiratory distress syndrome: results from animal and clinical studies.

Authors:  Shukun Hong; Chao Jian; Hongye Wang; Xincheng Wang; Luchuan Xing; Lujun Qiao
Journal:  BMC Pulm Med       Date:  2022-09-16       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.